Posted by Michael Wonder on 11 Nov 2022
CHMP issues opinion related to review of medicines within the Janus kinase inhibitor class
11 November 2022 - AbbVie announced today the EMA's CHMP has adopted an opinion following a nine month review of the benefit-risk of medicines within the Janus kinase inhibitor class for the treatment of inflammatory diseases, including Rinvoq (upadacitinib monohydrate).
The CHMP did not recommend changes to current Rinvoq indication statements.
